Dapagliflozin approved for heart failure across LVEFs
European Pharmaceutical Review
DECEMBER 12, 2022
The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF). AstraZeneca’s oral dapagliflozin drug.
Let's personalize your content